| Literature DB >> 32961576 |
Andreas Tiede1, Lorenzo Alberio2.
Abstract
Antibodies against factor VIII (FVIII) can be detected based on their ability to neutralize the procoagulant activity of FVIII (neutralizing antibodies, inhibitors), or based on their specific binding capacity to FVIII protein. This article reviews the available assays and their clinical interpretation in patients with congenital and acquired hemophilia. Thieme. All rights reserved.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32961576 DOI: 10.1055/a-1223-3353
Source DB: PubMed Journal: Hamostaseologie ISSN: 0720-9355 Impact factor: 1.778